Bio Therapeutic Drugs Company Investment Opportunity in Sydney, Australia

- Our groundbreaking recombinant formulation induces stem cell recruitment and differentiation, stimulating intervertebral disc cell matrix for regeneration and self-healing.

- Developed as an image-guided intra-disc administration under local anesthesia, ensuring precision and effectiveness in the therapeutic process.

- A therapeutic candidate for the regeneration of spinal intervertebral discs in patients with debilitating degenerative disc conditions.

- Induces the mobilization and differentiation of stem cells, leading to de novo regeneration of intervertebral discs and stabilization of the affected spine.

- Backed by a compelling biological rationale and a robust preclinical data set, demonstrating a strong proof of concept.

- Cure back pain with personalized, targeted, regenerative therapy via a non-invasive injection directly into the disc.

- Offers a cost-effective and quick procedure, aiming to enhance the quality of life for patients.

- Positioned in the $300 billion back pain industry, addressing a significant market need.

- Great investment opportunity at the seed stage, with RDTI registration in Australia reflecting a commitment to research and development.

- Administered as a convenient day procedure service, either in a radiology suite or a day procedure facility.

- Founded by individuals with decades of experience in the industry.

Biotech with a novel recombinant protein injection to cure back pain.

Issued patents; Trade secret IP around manufacturing,

New IP generation via contracted university research.

Use global contractors for manufacturing and regulatory support. We have rented facilities in India and Korea. The details of the facility will be disclosed after introduction.

Four shareholders including inventors and a strategic partner. No loans. Company registered for tax incentives. Selling equity to fund regulatory approval.